Sugammadex injection

University of California, Irvine · FDA-approved active Small molecule

Sugammadex injection is a Selective relaxant binding agent Small molecule drug developed by University of California, Irvine. It is currently FDA-approved for Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults undergoing surgery, Reversal of deep neuromuscular blockade in anesthetized patients. Also known as: Sugammadex, Group A, Sugammadex 100Mg/ml Intravenous Solution.

Sugammadex is a selective relaxant binding agent that encapsulates and inactivates steroidal neuromuscular blocking agents, rapidly reversing neuromuscular blockade.

Sugammadex is a selective relaxant binding agent that encapsulates and inactivates steroidal neuromuscular blocking agents, rapidly reversing neuromuscular blockade. Used for Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults undergoing surgery, Reversal of deep neuromuscular blockade in anesthetized patients.

At a glance

Generic name	Sugammadex injection
Also known as	Sugammadex, Group A, Sugammadex 100Mg/ml Intravenous Solution
Sponsor	University of California, Irvine
Drug class	Selective relaxant binding agent
Target	Steroidal neuromuscular blocking agents (rocuronium, vecuronium, pancuronium)
Modality	Small molecule
Therapeutic area	Anesthesia
Phase	FDA-approved

Mechanism of action

Sugammadex works by forming a tight 1:1 complex with steroidal neuromuscular blocking drugs (rocuronium, vecuronium, pancuronium) through host-guest chemistry, effectively removing them from the neuromuscular junction and plasma. This allows acetylcholine to restore normal neuromuscular transmission without requiring acetylcholinesterase inhibitors. The drug enables rapid and complete reversal of neuromuscular blockade induced during anesthesia.

Approved indications

• Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults undergoing surgery
• Reversal of deep neuromuscular blockade in anesthetized patients

Common side effects

• Transient increase in heart rate
• Hypotension
• Nausea
• Vomiting
• Recurrence of neuromuscular blockade

Key clinical trials

• The Occurrence of Emergence Agitation in Pediatric Strabismus Surgery (PHASE4)
• Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection (PHASE4)
• Sugammadex v.s. Neostigmine/Glycopyrrolate (NA)
• Sugammadex vs Neostigmine/Glycopyrrolate on Urinary Retention After Spine Surgery (PHASE4)
• Minimal Flow Anesthesia and Infection Risk (NA)
• The Effect of Methylprednisolone on the Reversal Time of Rocuronium by Sugammadex in the Pediatric Patient Group (PHASE4)
• The Effect of Deep Neuromuscular Block and Reversal With Sugammadex on Surgical Conditions and Perioperative Morbidity in Shoulder Surgery Using a Deltopectoral Approach (PHASE4)
• Perioperative Respiratory Adverse events_sugammadex (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Sugammadex injection CI brief — competitive landscape report
• Sugammadex injection updates RSS · CI watch RSS
• University of California, Irvine portfolio CI

Frequently asked questions about Sugammadex injection

What is Sugammadex injection?

Sugammadex injection is a Selective relaxant binding agent drug developed by University of California, Irvine, indicated for Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults undergoing surgery, Reversal of deep neuromuscular blockade in anesthetized patients.

How does Sugammadex injection work?

Sugammadex is a selective relaxant binding agent that encapsulates and inactivates steroidal neuromuscular blocking agents, rapidly reversing neuromuscular blockade.

What is Sugammadex injection used for?

Sugammadex injection is indicated for Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults undergoing surgery, Reversal of deep neuromuscular blockade in anesthetized patients.

Who makes Sugammadex injection?

Sugammadex injection is developed and marketed by University of California, Irvine (see full University of California, Irvine pipeline at /company/university-of-california-irvine).

Is Sugammadex injection also known as anything else?

Sugammadex injection is also known as Sugammadex, Group A, Sugammadex 100Mg/ml Intravenous Solution.

What drug class is Sugammadex injection in?

Sugammadex injection belongs to the Selective relaxant binding agent class. See all Selective relaxant binding agent drugs at /class/selective-relaxant-binding-agent.

What development phase is Sugammadex injection in?

Sugammadex injection is FDA-approved (marketed).

What are the side effects of Sugammadex injection?

Common side effects of Sugammadex injection include Transient increase in heart rate, Hypotension, Nausea, Vomiting, Recurrence of neuromuscular blockade.

What does Sugammadex injection target?

Sugammadex injection targets Steroidal neuromuscular blocking agents (rocuronium, vecuronium, pancuronium) and is a Selective relaxant binding agent.

Related

• Drug class: All Selective relaxant binding agent drugs
• Target: All drugs targeting Steroidal neuromuscular blocking agents (rocuronium, vecuronium, pancuronium)
• Manufacturer: University of California, Irvine — full pipeline
• Therapeutic area: All drugs in Anesthesia
• Indication: Drugs for Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults undergoing surgery
• Indication: Drugs for Reversal of deep neuromuscular blockade in anesthetized patients
• Also known as: Sugammadex, Group A, Sugammadex 100Mg/ml Intravenous Solution